Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at the 15th International Symposium on Hepatitis C Virus and Related Viruses

Redwood City, CA -- October 9, 2008 -- Genelabs Technologies, Inc. (Nasdaq:GNLB) announced that three presentations were made at the 15th International Symposium on Hepatitis C Virus and Related Viruses, each on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered by Genelabs.

The presentations focused on the discovery, in vitro antiviral activity, resistance profile, pharmacokinetics, and mechanism of action of GL60667 (NVP-LDI133), a potent non-nucleoside inhibitor of the HCV NS5B polymerase.

The presentations contain studies performed by both Genelabs and Novartis scientists in connection with the license and research collaboration commenced in June of 2006 between the companies, covering Genelabs non-nucleoside HCV polymerase inhibitors. GL60667 is one of a number of non-nucleoside HCV polymerase inhibitors discovered by Genelabs.

"The presentations made describe the discovery of new site 1 non-nucleoside polymerase inhibitors with potent anti-HCV activity" said Ronald C. Griffith, PhD, Genelabs' Chief Scientific Officer. "Other compounds from this class continue to advance forward in preclinical studies and we are very pleased with the progress made to date."

About Genelabs Technologies

Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage vaccine candidate for hepatitis E virus partnered with GlaxoSmithKline, the company is advancing both partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus.

For more information, please visit www.genelabs.com.